Characterization of a downstream gene therapeutic for the reparative treatment of severe fractures period of performance september 24, 2020 - november 23, 2021
Ended Awarded Last action
- Contract number
- 75N95020F00004
- Awardee
-
Lovelace Biomedical Research Institute UEI MBT9RXJJ7428
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,317,349
Award facts
- Contract value 42% obligated
-
- $1,317,349.00 Current, with exercised options
- $3,108,022.00 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Albuquerque, NM 87108, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$79,486 | |
| Supplemental Agreement for work within scope | $133,039 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $180,177 | |
| Supplemental Agreement for work within scope | $281,544 | |
| Supplemental Agreement for work within scope | $101,818 | |
| Original award | $700,257 |
About this award
This is a $3,108,022.00 cost-plus-fixed-fee delivery order contract awarded by the National Institute on Drug Abuse (NIDA) to the Lovelace Biomedical Research Institute, a non-profit preclinical contract research organization. The contract is for the characterization of a downstream gene therapeutic for the reparative treatment of severe fractures, with a period of performance from September 24, 2020 to November 23, 2021. This contract does not have a set-aside designation. Lovelace Biomedical Research Institute has extensive experience conducting nonclinical animal studies and providing preclinical research services to federal agencies like NIDA, FDA, and the Biomedical Advanced Research and Development Authority (BARDA). The institute also holds multiple federal contract IDVs for services like animal modeling, medicinal chemistry, and medical countermeasure testing.
Quick answers
Who was awarded contract 75N95020F00004?
75N95020F00004 was awarded to Lovelace Biomedical Research Institute by National Institute on Drug Abuse (National Institutes of Health) on September 22, 2020.
How much is contract 75N95020F00004 worth?
The government has obligated $1,317,349 on 75N95020F00004. Its potential value, with all options, is $3,108,022.
Is contract 75N95020F00004 an order under another contract?
Yes. 75N95020F00004 is a delivery order under 75N95019D00012, an indefinite delivery contract.
Was contract 75N95020F00004 competed?
The extent of competition for 75N95020F00004 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award